Reovirus Seeks Out and Destroys Cancer Cells, Preliminary Study Results Show
Posted on: Monday, 5 December 2005, 06:00 CST
CALGARY, Alberta, Dec. 5 /PRNewswire/ -- For the first time, researchers have demonstrated that the reovirus, a naturally occurring virus found in the environment, can seek out and destroy cancer cells in a variety of tumor types and locations when delivered intravenously to patients.
Preliminary results from an ongoing patient study in the United Kingdom have demonstrated that Reolysin was well-tolerated by patients and there was evidence of virus replication within several types of tumors in patients who had failed all previous treatments. Of 12 patients who received doses of Reolysin on five consecutive days, at least four patients had stabilization of the measured tumor. Patients who experienced tumor activity included those with colorectal, prostate, non-small-cell lung and bladder cancers.
These early results, presented by Dr. Johann S. de Bono of the Royal Marsden Hospital in London at the most recent AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, showed that the reovirus, when delivered intravenously, enters cancer cells, replicates within them and ultimately kills them. It works by replicating within cancer cells that have an activated Ras pathway, a common mutation that is shared by approximately two thirds of all human cancers.
"We believe that these early results are the most encouraging data we have seen to date in our work with Reolysin," says Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc., the company sponsoring the study.
Oncolytics has also started patient enrolment in a similar intravenous trial in the United States at the Montefiore Medical Center in New York City. This clinical trial is an open-label, dose-escalation Phase I study in which a single dose of Reolysin is administered intravenously to patients with advanced and/or metastatic solid tumors.
For more information about Reolysin, or Oncolytics Biotech, log on to http://www.oncolyticsbiotech.com/.
Oncolytics Biotech Inc.
CONTACT: Janet Vasquez, +1-212-825-3210, for Oncolytics Biotech Inc.
Web site: http://www.oncolyticsbiotech.com/
Source: PRNewswire
Related Articles
- Study Suggests Survival Benefit From Radioactive Microsphere Therapy in Patients With Colorectal Cancer Liver Metastases Who Have Failed Chemotherapy
- Avantogen and Innovate Oncology Announce Presentation of Clinical Data Demonstrating Extended Survival in Patients With Pancreatic Cancer Treated With RP101
- Synchronous Primary Neoplasms Detected on ^Sup 18^F-FDG PET in Staging of Patients With Esophageal Cancer
- NeoRx Announces Treatment of First Patient With Picoplatin in Phase 2 Clinical Trial in Small Cell Lung Cancer
- Regeneron's VEGF Trap Demonstrates Positive Preliminary Results From Single-Agent Phase 1 Trial in Patients With Advanced Cancer; Results Presented at ASCO Annual Meeting on May 16, 2005
- Aphton Reports Significant Activity of IGN101 in Patients With Epithelial Cancers
- Study: Cell Phones Won't Raise Brain Tumor Risk
- Australian Cancer Technology Reports Doubling of Mean Survival Time in Patients With Pancreatic Cancer Using RP101 With Chemotherapy Treatment
- National Cancer Institute Reports Encouraging Results With Delcath Cancer Therapy
- Palliative Treatment of Painful Disseminated Bone Metastases With ^Sup 186^Rhenium-HEDP in Patients With Lung Cancer
 |
 |
User Comments (0)
RSS Feeds